Epithelial Cell Adhesion Molecule

A cell adhesion molecule that is expressed on the membranes of nearly all EPITHELIAL CELLS, especially at the junctions between intestinal epithelial cells and intraepithelial LYMPHOCYTES. It also is expressed on the surface of ADENOCARCINOMA and epithelial tumor cells. It may function in the MUCOSA through homophilic interactions to provide a barrier against infection. It also regulates the proliferation and differentiation of EMBRYONIC STEM CELLS.

Also Known As:

Networked: 2381 relevant articles (79 outcomes, 317 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gires, Olivier: 34 articles (10/2021 - 04/2003)
2.	Baeuerle, Patrick A: 27 articles (01/2020 - 06/2003)
3.	Pantel, Klaus: 23 articles (01/2022 - 07/2003)
4.	Krishnakumar, Subramanian: 19 articles (11/2020 - 12/2004)
5.	Spizzo, Gilbert: 18 articles (01/2018 - 04/2002)
6.	Lindhofer, Horst: 17 articles (10/2021 - 11/2005)
7.	Yamashita, Taro: 16 articles (08/2021 - 11/2007)
8.	Park, Young Nyun: 15 articles (01/2022 - 03/2011)
9.	Duan, Wei: 14 articles (01/2022 - 05/2011)
10.	Gastl, Guenther: 14 articles (01/2016 - 05/2004)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2023 - "Complete tumor eradication only occurred when EpCAM and CD133 were targeted simultaneously and lead to full remission in 80% of the test mice. " 12/28/2022 - "Furthermore, EpCAM aptamer arrays showed improved tolerance against competing targets in an extracellular environment and potent bioavailability and targeting specificity in a xenograft tumor model in mice. " 06/16/2023 - "We observed a significant reduction of EpCAM-positive cells in both cancer patients and contaminated blood, which was comparable to the negative control after leucodepletion. " 04/01/2019 - "This multi-nanoparticles showed significantly high-EpCAM tumor targeting and lower toxicity, and enhanced immune therapeutic efficacy. " 10/01/2005 - "A combination of cytology and RT-PCR analysis of CEA and Ep-CAM significantly improved the detection sensitivity of tumor cells in serous effusions. "
2.	Breast Neoplasms (Breast Cancer) 06/30/2022 - "Results determined the EINP efficacy against EpCAM positive MCF-7 breast cancer at 24, 48, and 72 h were 69.11%, 77.84%, and 74.6%, respectively, demonstrating that the EINPs achieved greater cytotoxic efficacy supported by NIS-mediated Na131I uptake than the non-targeted 131INPs and Na131I. " 10/01/2022 - "The TT-RBC-NPs enabled enhanced cytotoxic efficacy against EpCAM positive MCF-7 breast cancer over the non-targeted NPs. " 04/01/2022 - "We further confirm the efficacy of the AFM chip with five advanced breast cancer patients' whole blood to capture EpCAM+/CK19+/CD45-/DAPI + CTCs. " 01/01/2022 - "In this study, breast cancer cells were transfected with N-glycosylation mutation EpCAM plasmid to express deglycosylated EpCAM. " 01/01/2021 - "Thus, the main goal of our study was to target either VEGFR2 or EpCAM as pivotal players in the progression of angiogenesis in breast cancer. "
3.	Ovarian Neoplasms (Ovarian Cancer) 03/01/2019 - "The present study evaluated the role of IL‑6 and IL‑8 in the expression of EpCAM in the A2780 human ovarian cancer cell line. " 07/12/2011 - "This study provides insights in transcriptional regulation of epcam in ovarian cancer. " 06/01/2023 - "The 8-channel flow cytometry of clinical samples showed that the EpCAM expression and lymphocyte infiltration were significantly heterogeneous among ovarian cancer patients and lesions at different sites. " 06/01/2023 - "The results of the bioinformatic analysis showed that the expression of EpCAM in ovarian cancer tissue was significantly higher than that in normal ovarian tissue. " 06/01/2023 - "The EpCAM expression and immune cell infiltration in different foci of ovarian cancer were detected by 8-channel flow cytometry. "
4.	Neoplasm Metastasis (Metastasis) 10/15/2010 - "First, RNAi-mediated knockdown of Ep-CAM partially relieved metastasis suppression imposed by G9a suppression. " 09/23/2016 - "Detection of CTCs classified by EpCAM in peripheral blood is helpful in evaluating the distant metastasis and treatment effectiveness of NSCLC patients." 09/01/2023 - "EpCAM revealed high expression in 60% of the cases with significant association with higher grade, nodal metastasis, and advanced stage (p < 0.001 for each). " 03/01/2023 - "There were 39 samples with metastases and strong expression of EpCAM (34.5%), while 21 samples with weak expression (18.6%). " 01/01/2023 - "We also demonstrated that a higher percentage of CD24+CD44+CD54+EpCAM+ cells was positively associated with metastasis. "
5.	Circulating Neoplastic Cells 01/01/2020 - "So far, studies on circulating tumor cells (CTCs) in BTC are insufficient to promote their use in patient clinical management and are limited to EpCAM-enriched CTCs evaluated with the CellSearch. " 07/01/2023 - "The proposed strategy of nondestructive separation/enrichment and SERS-based sensitive enumeration is promising for reliable analysis of EpCAM-positive CTCs in blood, which is expected to provide a powerful tool for analysis of extremely rare circulating tumor cells in complex peripheral blood for liquid biopsy." 08/15/2022 - "In situ signal amplification improves the capture efficiency of circulating tumor cells with low expression of EpCAM." 10/02/2021 - "CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM." 03/01/2021 - "The preliminary comparison with Cellsearch was also conducted, indicating that the cell membrane-semblance AMLVEpCAM showed higher capture performance for different kinds of EpCAM-expressed circulating tumor cells in the peripheral blood (4.4 ± 1.2-fold for AMLVEpCAM vs CellsearchTM, n=5, P<0.001). "

Related Drugs and Biologics

1.	Epithelial Cell Adhesion Molecule
2.	Antibodies
3.	catumaxomab
4.	Cadherins (E-Cadherin)
5.	Biomarkers (Surrogate Marker)
6.	Vimentin
7.	Immunotoxins (Immunotoxin)
8.	Doxorubicin (Adriamycin)
9.	Solitomab
10.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Drug Therapy (Chemotherapy)
4.	Neoadjuvant Therapy
5.	Precision Medicine